Thryv Therapeutics Announces FDA IND Clearance of THRV-1268 for Long QT Syndrome
Summary
Thryv Therapeutics announced FDA clearance of its IND application for THRV-1268 in Long QT Syndrome Type 2. The company said it plans to start its Phase 2/3 WAVE II clinical study in 2026. Thryv also disclosed new financing to support the registrational program and the clinical study launch. The company described THRV-1268 as a novel SGK1 inhibitor with potential across multiple cardiovascular diseases.
Funding
Amount
None
Total raised
Date
September 17, 2025
Announcement date
Investors
adMare BioInnovations, CTI Life Sciences Fund, Fonds de solidarité FTQ
Lead investors
Company
thryvtrx.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected